Hält derzeit Positionen bei aTyr Pharma Inc and Fate Therapeutics Inc
Position | Company | Period |
---|---|---|
Director | aTyr Pharma Inc | 1. November 2017 - |
Vice Chairman of the Board | Fate Therapeutics Inc | 1. Januar 2017 - |
Independent Director | Editas Medicine Inc | 1. Januar 2016 - 27. März 2018 |
Chief Executive Officer, Director | aTyr Pharma Inc | 1. Dezember 2015 - 1. November 2017 |
Vice Chairman of the Board | Fate Therapeutics Inc | None - |
Chief Executive Officer and Executive Chairman, Board of Directors | aTyr Pharma Inc | 1. September 2011 - 1. Dezember 2015 |
Suchen
Datum der Benachrichtigung | Datum der Transaktion | K/V Art der Transaktion |
Anz. der Aktien Kurs Wert |
Anzahl der Aktien | Kurs | Gesamtwert | Details | |
---|---|---|---|---|---|---|---|---|
2023-01-13 | 2023-01-13 |
Fate Therapeutics Inc
(FATE)
|
K Kauf |
36.631
+14.9%
5,43198.906 USD |
36.631 +14.9% | 5,43 | 198.906 USD | |
2023-01-13 | 2023-01-11 |
Fate Therapeutics Inc
(FATE)
|
K Kauf |
88.048
+55.7%
5,67499.232 USD |
88.048 +55.7% | 5,67 | 499.232 USD | |
2022-06-06 | 2022-06-03 |
Fate Therapeutics Inc
(FATE)
|
V Verkauf |
1.364
-0.9%
22,7931.086 USD |
1.364 -0.9% | 22,79 | 31.086 USD | |
2022-03-11 | 2022-03-10 |
Fate Therapeutics Inc
(FATE)
|
GV Geplanter Verkauf |
12.069
-7.0%
35,48428.208 USD |
12.069 -7.0% | 35,48 | 428.208 USD | |
2022-03-11 | 2022-03-10 |
Fate Therapeutics Inc
(FATE)
|
GV Geplanter Verkauf |
19.493
-10.2%
34,73676.992 USD |
19.493 -10.2% | 34,73 | 676.992 USD |